Jeff Himawan joined EW in 1999 and serves as Managing Director to the firm’s legacy venture capital funds Essex Woodlands Funds VI, VII and VIII. He has over 20 years of experience as a scientist, entrepreneur and venture capitalist and specializes in investments in the pharmaceutical sector.
Prior to EW, he began his industrial career in 1987 as a bench scientist at Genzyme Corporation. In 1996, he co-founded Seed-One Ventures, a venture capital firm which specializes in the initial formation, financing, and early operational development of technology-based companies. As a Managing Director at Seed-One Ventures, he led the formation and management of Elusys Therapeutics, Inc., a Fund IV company.
He currently serves on the Board of Directors of MediciNova, Horizon Pharma, Light Sciences Oncology and Catalyst Biosciences (CBIO) and as an Observer on the Board of Directors for Symphogen.
Dr. Himawan holds a Bachelor of Science degree from the Massachusetts Institute of Technology and a Doctor of Philosophy degree from Harvard University.